GALT
Galectin Therapeutics Inc.
There isn't enough reported data to score GALT yet.
GALT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
GALT's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
GALT PE Valuation
GALT has no meaningful PE right now: it lost money over the past year.
GALT Forward outlook
There aren't enough analyst estimates for GALT to show an outlook.
GALT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.43 | +$0.21 |
| Q1 2026 | -$0.41 | +$0.31 |
| Q4 2025 | -$0.48 | +$0.28 |
| Q3 2025 | -$0.59 | +$0.14 |
| Q2 2025 | -$0.64 | +$0.15 |
| Q1 2025 | -$0.72 | +$0.02 |
| Q4 2024 | -$0.76 | -$0.02 |
| Q3 2024 | -$0.73 | +$0.03 |
GALT is still losing money, but less than at its worst: $0.43 per share over the past year, against $0.79 at its worst in mid-2024.
GALT Quarterly Revenue
GALT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.4M | +$4.2M |
| Q1 2026 | -$3.9M | +$3.8M |
| Q4 2025 | -$6M | +$6.7M |
| Q3 2025 | -$3.5M | +$5M |
| Q2 2025 | -$6.6M | +$1.7M |
| Q1 2025 | -$7.7M | +$4.4M |
| Q4 2024 | -$12.8M | -$8.1M |
| Q3 2024 | -$8.5M | -$901K |
GALT has burned cash in almost every quarter: −$16M over the past year, against −$36M the year before.
GALT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +93K shares |
| 1 year | +3.8% | +2.4M shares |
| 3 years | +11% | +6.3M shares |
| 5 years | +13% | +7.6M shares |
| Available history | +16% | +9.2M shares |
GALT has 66M diluted shares, up 3.8% from a year ago.
GALT Net Leverage
GALT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GALT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.9 | Neutral |
| Stochastic | 21.4 | Neutral |
GALT's weekly RSI is 45 (neutral) and its Stochastic is 21 (neutral).
GALT PE vs Healthcare Sector
| Metric | GALT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GALT has no meaningful PE right now: it lost money over the past year.
GALT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.52 | 11% below |
| 20 week MA | $3.72 | 16% below |
| 50 week MA | $3.37 | 6.8% below |
| 100 week MA | $3.05 | 3% above |
| 200 week MA | $2.59 | 21% above |
GALT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 21% above its 200-week average.
GALT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.88 | $2.42 | -16% |
| 2021 | $2.42 | $2.37 | -2.1% |
| 2022 | $2.37 | $1.22 | -49% |
| 2023 | $1.22 | $1.66 | +36% |
| 2024 | $1.66 | $1.15 | -31% |
| 2025 | $1.15 | $4.05 | +252% |
| 2026 YTD | $4.05 | $3.14 | -22% |
GALT's yearly returns have swung widely, from +252% in 2025 to −49% in 2022. It's down 22% so far in 2026.